Patents by Inventor David E. Lanar

David E. Lanar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
    Patent number: 8268615
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 18, 2012
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
    Publication number: 20100040640
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 18, 2010
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Expression, purification and uses of a liver stage antigen 1 polypeptide
    Patent number: 7550275
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: June 23, 2009
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Recombinant merozoite protein-1 p42 vaccine
    Patent number: 7150875
    Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
  • AMA-1 protein and uses thereof
    Patent number: 7060276
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: June 13, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
  • AMA-1 protein and uses thereof
    Patent number: 7029685
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: April 18, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
  • Recombinant P. vivax merozoite protein-1 p42 vaccine
    Publication number: 20030157650
    Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: March 18, 2002
    Publication date: August 21, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
  • Plasmodium falciparum AMA-1 protein and uses thereof
    Publication number: 20030138450
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
    Type: Application
    Filed: October 15, 2002
    Publication date: July 24, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P.V. Nair
  • Plasmodium falciparum AMA-1 protein and uses thereof
    Publication number: 20030032787
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: March 25, 2002
    Publication date: February 13, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P.V. Nair